Migraine Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2022

January 2018 | 172 pages | ID: MA9D28EEA52EN
Azoth Analytics

Abstracts

Executive Summary

The report presents the market potential of seven major pipeline drugs meant for the treatment of migraine. These seven drugs that fall in the various categories of Ergotamines, Anti 5-HT Receptor Agonists and Anti-CGRPs by mechanism of action have been recognized as being clinically effective in migraine treatment. Expected to be launched in the market within the next 4-5 years, these seven potential drugs are likely to bring about major changes in the way migraine is treated globally.

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Migraine Pipeline Drugs Market by assessing the potential of the seven drugs that will be launched in the near future. Also, the report assesses the results of various clinical trials undertaken for each of the seven drugs, the product profile, description and regulatory phase of each of the seven drugs. Also, 7Ps Analysis (Patent, Phase, Pathway, Patient, Physician, Payer, Partner) has been done for each of the seven drugs to present the current perspective.

The report titled “Migraine Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2022” also analyzes the overall sizing, growth and forecast of Migraine Drugs Market By Type (Acute and Prophylaxis) for the global market as well as for countries including United States, United Kingdom, Japan, France, Italy and Germany.

Over the recent years, the Migraine Drugs market is growing rapidly due to rising prevalence of migraine patients around the world. Globally, the growth of Migraine Drugs market is driven by rising awareness regarding migraine and available treatments

The global migraine drugs market is projected to display a robust growth represented by a CAGR of 14.48% during 2017– 2022, chiefly driven by rising consumption of unhealthy food coupled with unmet need By the present drugs for the treatment of migraine. The report has covered and analysed the present migraine drugs in the market and has also analysed potential of seven major pipeline drugs. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global migraine pipeline drugs market.

Scope of the Report

Migraine Pipeline Drugs Assessment - Drug X1, X2, X3, X4, X5, X6, X7 (Forecast Period: 2019-2022)

• Market Potential
• Clinical Trials
• Product Description
• Regulatory Phases
• 7Ps Analysis

Global Migraine Drugs Market (Actual Period: 2012-2016, Forecast Period: 2017-2022)

• Market Sizing and Growth
• Market Sizing and Growth By Type - Acute and Prophylaxis

Country Analysis US, UK, Japan, France, Italy, Germany (Actual Period: 2012-2016, Forecast Period: 2017-2022)

• Market Sizing and Growth

Other Report Highlights

• Market Dynamics - Drivers, Challenges
• Company Analysis - Amgen Biopharmaceuticals, Allergan, Eli Lilly, Alder Pharmaceuticals, Teva Pharmaceutical, Vernalis, Pfizer, Impax Laboratories, Glaxo Smithkline

Customization of the Report

The report could be customized according to the client s specific research requirements. No additional cost will be required to pay for limited additional research.

Contents

1. RESEARCH METHODOLOGY

2. EXECUTIVE SUMMARY

3. MIGRAINE - AN OVERVIEW

3.1. Symptoms of migraine
3.2. Stages of Migraine
3.3.Types of Migraine
3.4. Types of migraine on the basis of frequency of occurrence

4. TREATMENT OF MIGRAINE

4.1. Goal of Migraine Treatment
4.2. Treatment of Migraine - Pharmacological and Non-Pharmacological
  4.2.1. Pharmacological treatment of migraine
  4.2.2. Pharmacological - Abortive
  4.2.3. Pharmacological - Preventive
  4.2.4. Non-Pharmacological Treatment of Migraine
  4.2.5. Non- Pharmacological - Surgical
  4.2.6. Non- Pharmacological - Non-Surgical

5. ANTI-MIGRAINE PIPELINE DRUGS ANALYSIS

5.1. Anti-Migraine Pipeline Drugs (According to Mechanism of Working)
5.2. Anti-Migraine Pipeline Drugs (Ergotamine): Drug - X1
  5.2.1. Description
  5.2.2. Regulatory Milestones
  5.2.3. Advantages & Disadvantages
  5.2.4. Product Profile & Expected Launch
  5.2.5. Clinical Trials and Status
  5.2.6. Pivotal Clinical Trials and Results
  5.2.7. Drug X-1- Global Market Potential
  5.2.8. Drug X-1- 7Ps Analysis
5.3. Anti-Migraine Pipeline Drugs (Anti-5HT Receptor Agonist): Drug - X2
  5.3.1. Description
  5.3.2. Regulatory Milestones
  5.3.3. Advantages & Disadvantages
  5.3.4. Product Profile & Expected Launch
  5.3.5. Clinical Trials and Status
  5.3.6. Pivotal Clinical Trials and Results
  5.3.7. Drug - X2 - Global Market Potential
  5.3.8. Drug - X2 - 7Ps Analysis
5.4. Anti-Migraine Pipeline Drugs (Anti CGRPs)
5.5. Anti-Migraine Pipeline Drugs (Anti CGRPs) - By Drug
5.6. Anti-Migraine Pipeline Drugs (CGRP Antagonist): Drug - X3
  5.6.1. Description
  5.6.2. Regulatory Milestones
  5.6.3. Advantages & Disadvantages
  5.6.4. Product Profile & Expected Launch
  5.6.5. Clinical Trials and Status
  5.6.6. Pivotal Clinical Trials and Results
  5.6.7. Drug - X3 - Global Market Potential
  5.6.8. Drug - X3 - 7Ps Analysis
5.7. Anti-Migraine Pipeline Drugs (Anti-CGRP Mab): Drug - X4
  5.7.1. Description
  5.7.2. Regulatory Milestones
  5.7.3. Advantages & Disadvantages
  5.7.4. Product Profile & Expected Launch
  5.7.5. Clinical Trials and Status
  5.7.6. Pivotal Clinical Trials and Results
  5.7.7. Drug - X4 - Global Market Potential
  5.7.8. Drug - X4 - 7Ps Analysis
5.8. Anti-Migraine Pipeline Drugs (Anti-CGRP Mab): Drug - X5
  5.8.1. Description
  5.8.2. Regulatory Milestones
  5.8.3. Advantages & Disadvantages
  5.8.4. Product Profile & Expected Launch
  5.8.5. Clinical Trials and Status
  5.8.6. Pivotal Clinical Trials and Results
  5.8.7. Drug - X5 - Global Market Potential
  5.8.8. Drug - X5 - 7Ps Analysis
5.9. Anti-Migraine Pipeline Drugs (Anti-CGRP Mab): Drug - X6
  5.9.1. Description
  5.9.2. Regulatory Milestones
  5.9.3. Advantages & Disadvantages
  5.9.4. Product Profile & Expected Launch
  5.9.5. Clinical Trials and Status
  5.9.6. Pivotal Clinical Trials and Results
  5.9.7. Drug - X6 - Global Market Potential
  5.9.8. Drug - X6 - 7Ps Analysis
5.10. Anti-Migraine Pipeline Drugs (Anti-CGRP Mab): Drug - X7
  5.10.1. Description
  5.10.2. Regulatory Milestones
  5.10.3. Advantages & Disadvantages
  5.10.4. Product Profile & Expected Launch
  5.10.5. Clinical Trials and Status
  5.10.6. Pivotal Clinical Trials and Results
  5.10.7. Drug - X7 - Global Market Potential
  5.10.8. Drug - X7 - 7Ps Analysis

6. GLOBAL MIGRAINE DRUGS MARKET: GROWTH AND FORECAST

6.1. By Value (2012-2016)
6.2. By Value (2017-2022)

7. GLOBAL MIGRAINE DRUGS MARKET - ANALYSIS BY TYPE

7.1. Global Migraine Drugs Market, By Type: Breakdown (%)
  7.1.1. Global Migraine Drugs Market- By Type: 2016 (%)
  7.1.2. Global Migraine Drugs Market By Type: 2022 (%)
7.2. Global Migraine Drugs Market- By Acute
  7.2.1. By Value (2012-2016)
  7.2.2. By Value (2017-2022)
7.3. Global Migraine Drugs Market- By Prophylaxis
  7.3.1. By Value (2012-2016)
  7.3.2. By Value (2017-2022)

8. GLOBAL MIGRAINE DRUGS MARKET: COUNTRY ANALYSIS (U.S, U.K, JAPAN, FRANCE, ITALY, GERMANY, ROW)

8.1. U.S. Migraine Drugs Market, By Value (2012-2022)
8.2. U.K. Migraine Drugs Market, By Value (2012-2022)
8.3. Japan Migraine Drugs Market, By Value (2012-2022)
8.4. France Migraine Drugs Market, By Value (2012-2022)
8.5. Italy Migraine Drugs Market, By Value (2012-2022)
8.6. Germany Migraine Drugs Market, By Value (2012-2022)
8.7. ROW Migraine Drugs Market, By Value (2012-2022)

9. MARKET DYNAMICS

9.1. Migraine Drug Market Drivers
9.2. Migraine Drug Market Challenges

10. COMPANY PROFILES

10.1. Amgen
10.2. Allergan
10.3. Eli Lilly
10.4. Alder Pharmaceuticals
10.5. Teva Pharmaceuticals
10.6. Vernalis
10.7. Pfizer
10.8. Impax Laboratories
10.9. Glaxo Smithkline

List Of Figures

LIST OF FIGURES

Figure 1: 2 hour pain relief & pain free rates in patients treated with LEVADEX (MAP0004) compared to placebo (1st pivotal trial)
Figure 2: Improvement at two hours in people who took LEVADEX compared to Placebo (2nd pivotal trial)
Figure 3: Global Drug - X1 Market Size, By Value, Forecast, 2019-2022 (USD Billion)
Figure 4: Percentage of patients achieving primary end point
Figure 5: Percentage of patients achieving secondary endpoint
Figure 6: Global Drug - X2 Market Size, By Value, Forecast, 2019-2022 (USD Million)
Figure 7: Efficacy in 2 hour pain freedom
Figure 8: Global Drug - X3 Market Size, By Value, Forecast, 2019-2022 (USD Billion)
Figure 9: Reduction in Monthly migraine days - weeks 1 through
Figure 10: Percentage of patients with =75% reduction in number of migraine days - weeks 1 through
Figure 11: Percentage of patients with 100% response rate (no migraine in any given month) - months 1 through
Figure 12: Global Drug - X4 Market Size, By Value, Forecast, 2019-2022 (USD Million)
Figure 13: Global Drug - X5 Market Size, By Value, Forecast, 2019-2022 (USD Million)
Figure 14: Global Drug - X6 Market Size, By Value, Forecast, 2019-2022 (USD Million)
Figure 15: Monthly migraine days reduction vs placebo in previous prophylactic drugs failure group
Figure 16: Reduction in days using acute pain medications in recent drug overuse group
Figure 17: Global Drug - X7 Market Size, By Value, Forecast, 2019-2022 (USD Million)
Figure 18: Global Migraine Drugs Market Size, By value, 2012-2016 (USD Billion)
Figure 19: Global Migraine Drugs Market Size, By Value, Forecast, 2017-2022 (USD Billion)
Figure 20: Global consumption of chocolate confectionary, By volume (in 1000 metric tones)
Figure 21: Global Migraine Drugs Market Share, By Type, 2016 (%)
Figure 22: Global Migraine Drugs Market Share, By Type, 2022 (%)
Figure 23: Global Migraine Drugs Market, By Acute, By Value, 2012-2016 (USD Million)
Figure 24: Global Migraine Drugs Market, By Acute, By Value, 2017-2022 (USD Million)
Figure 25: Global Migraine Drugs Market, By Prophylaxis, By Value, 2012-2016 (USD Million)
Figure 26: Global Migraine Drugs Market, By Prophylaxis, By Value, 2017-2022 (USD Million)
Figure 27: U.S. Migraine Drugs Market, By Value, 2012-2016 (USD Billion)
Figure 28: U.S. Migraine Drugs Market, By Value, 2017-2022 (USD Billion)
Figure 29: U.S Adult Migraine Patients, In Percentage
Figure 30: U.S Migraine Patients, By gender, In Percentage
Figure 31: U.K Migraine Drugs Market, By Value, 2012-2016 (USD Billion)
Figure 32: U.K. Migraine Drugs Market, By Value, 2017-2022 (USD Billion)
Figure 33: U.K. Migraine Patient, In Percentage
Figure 34: NHS Budget for mental illness, In Billion
Figure 35: Japan Migraine Drugs Market, By Value, 2012-2016 (USD Billion)
Figure 36: Japan Migraine Drugs Market, By Value, 2017-2022 (USD Billion)
Figure 37: Japan Migraine Patient out of total population, In Percentages
Figure 38: France Migraine Drugs Market, By Value, 2012-2016 (USD Billion)
Figure 39: France Migraine Drugs Market, By Value, 2017-2022 (USD Billion)
Figure 40: France Migraine Patient, In Percentage
Figure 41: Unemployment rate in France in percentage
Figure 42: Italy Migraine Drugs Market, By Value, 2012-2016 (USD Billion)
Figure 43: Italy Migraine Drugs Market, By Value, 2017-2022 (USD Billion)
Figure 44: Italy Migraine Patient out of total population, In Percentages
Figure 45: Italy Unemployment rate, In Percentages
Figure 46: Germany Migraine Drugs Market, By Value, 2012-2016 (USD Billion)
Figure 47: Germany Migraine Drugs Market, By Value, 2017-2022 (USD Billion)
Figure 48: Germany Migraine Patient out of total population, In Percentages
Figure 49: First Time asylum application, In Number
Figure 50: ROW Migraine Drugs Market, By Value, 2012-2016 (USD Billion)
Figure 51: ROW Migraine Drugs Market, By Value, 2017-2022 (USD Billion)
Figure 52: Total global sales of Allergan's Botox in 2016 and forecasted for 2022 (USD Million)

List Of Tables

LIST OF TABLES

Table A: Summary of Completed Clinical Trials of Drug - X1
Table B: Summary of Completed & ongoing Clinical Trials of Drug - X1
Table C: Summary of Completed & ongoing Clinical Trials of Drug - X1
Table D: Number and percentage of patients who reported each particular TEAE with safety population for each dose.
Table E: Summary of Completed & ongoing Clinical Trials of Drug - X2
Table F: Summary of Completed & ongoing Clinical Trials of Drug - X3
Table G: Summary of Completed Clinical Trials of Drug - X4
Table H: Summary of Ongoing Clinical Trials of Drug - X5
Table I: Summary of Completed & Ongoing Clinical Trials of Drug - X6
Table J: Summary of Completed & Ongoing Clinical Trials of Drug - X7